Doug Galasko - Concepedia

Author

Doug Galasko

Also Known As

D GALASKO, D Galasko, D. Galasko, Doug Galasko, Doug R Galasko, Doug R. Galasko, Douglas Galasko, Jan Hamer, Marta Milà‐Alomà

Publications

Citations

H-Index

Concepts

All Affiliations

University of California San Diego Indiana University – Purdue University Indianapolis University of Pittsburgh Institute for Neurodegenerative Disorders National Institute on Aging

About

Doug Galasko is an author at University of California San Diego specializing in neurology, medicine, and alzheimer's disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	1.1K
2	Neurology	4	4	1.1K
3	Health Sciences	2	2	818
4	Geriatrics	2	2	818
5	Cell Biology	1	1	170

Doug Galasko

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Doug Galasko, David Bennett, Mary Sano, PubMed Disease Cooperative StudyAgingAd PatientsGeriatric NeurologyAlzheimer's Disease	1997	774
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort Kenneth Marek, Sohini Chowdhury, Andrew Siderowf, Annals of Clinical and Translational Neurology	2018	633
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) John C. Morris, S. D. Edland, Christine Clark, Neurology	1993	437
APOE ϵ4 Increases Risk for Dementia in Pure Synucleinopathies Debby W. Tsuang, James B. Leverenz, Oscar L. López, JAMA Neurology	2012	379
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort Tanya Simuni, Andrew Siderowf, Shirley Lasch, Movement Disorders	2018	199
Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer’s disease Joseph R. Herdy, Larissa Traxler, Ravi Kant Agarwal, Cell stem cell Neurodegenerative DiseasesAlzheimer's DiseaseAgingMedicineAged Human Neurons	2022	170
<i>GBA</i> mutations increase risk for Lewy body disease with and without Alzheimer disease pathology Debby W. Tsuang, James B. Leverenz, Oscar L. López, Neurology	2012	155
Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease Doug Galasko, Christopher M. Clark, Lei Chang, Neurology	1997	155
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study Tanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, The Lancet Neurology Dopamine TransporterParkinson DiseaseNeuroscienceNeurologyDopamine	2019	135
Human Apolipoprotein E Isoform‐Specific Differences in Neuronal Sprouting in Organotypic Hippocampal Culture Bruce Teter, Pengcheng Xu, John R. Gilbert, Journal of Neurochemistry	1999	90

Page 1